A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy

European Journal of Ophthalmology

Volumn 13, Issue 5, 2003, Pages 461-467

  Moschos, Michael N ^a,c   Panayotidis, D ^a   Moschos, M M ^b   Bouros, Chr ^a   Theodossiadis, P G ^a   Theodossiadis, G P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b JULES GONIN EYE HOSPITAL   (Switzerland)

^c NONE   (Greece)

Author keywords

Choroidal neovascularization; Multifocal electroretinogram; Myopia; Photodynamic therapy; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIODE LASER; ELECTRIC POTENTIAL; ELECTRORETINOGRAM; ELECTRORETINOGRAPHY; EVALUATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MALE; MULTIFOCAL ELECTRORETINOGRAM; MYOPIA; OPHTHALMOSCOPY; OUTCOMES RESEARCH; PARAMETER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RELIABILITY; RETINA FOVEA; RETINA MACULA LUTEA; SUBRETINAL NEOVASCULARIZATION; TECHNIQUE; VISUAL ACUITY;

EID: 0037716486     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210301300507     Document Type: Article

References (12)

1. American Academy of Ophthalmology. Age-related macular degeneration - Preferred pattern. San Francisco: American Academy of Ophthalmology; 1998. www.aao.org/aao/newsroom/facts/amd.cfm.
2. Cutrin BJ. Myopias. Philadelphia: Harper & Row; 1985: 309-30.
3. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-14.
4. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001; 131: 541-60.
5. Yoshida T, Ohno K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia. Ophthalmology 2001; 109: 712-9.
6. American Academy of Ophthalmology. Photodynamic technology with verteporfin for age-related macular degeneration. Ophthalmology 2000; 107: 2314-7.
7. Sickenberg M, Schmidt-Erfurth U, Miller WJ, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic cases. Arch Ophthalmol 2000; 118: 327-36.
8. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report 1. Ophthalmology 2001; 108: 841-52.
9. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
10. Husain D, Kramer M, Kenney AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularisation and normal retina and choroid up to seven weeks after treatment. Invest Ophthalmol Vis Sci 1999; 105: 2322-31.
11. Kramer M, Miller JW, Michaud P, et al. Liposomal benzoporphyrin derivative verteporfin in photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996; 103: 427-38.
12. Sutter EE, Tran D. The field topography of ERG in man, 1. The photopic luminance response. Vision Res 1992; 32: 433-66.